Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The more I learn about this Hitler guy the less I care for him.
Also: even a blind squirrel occasionally finds a few nuts.
Is it true sushi Man? Can you find the nuts in the dark?
Compare lose/loose
“…should have…” not “…should of…”
You said, “Mark my words!”
The pronunciation is the same so I can see where you got confused.
From Cantor, Dec 9
We view the increase in eGFR over time and lower UPCR at each time point in AURORA 2 as positive and suggestive of disease modification for years. We know from AURORA 1 that eGFR with voclosporin initially declines, though we view it as positive that over the three-year period in AURORA 2 that eGFR remained stable and increased over control at the end, which we think suggests benefit over time. We think lower UPCR at every time point is very positive, as proteinuria has been known to be the most common disease manifestation, and lower UPCR has been shown to lead to improvement in disease. We think that showing LUPKYNIS has a continuously lower UPCR compared to standard of care over three years is very supportive of an improved efficacy profile.
It could take years and several trials. It could be a few months as well. I’m willing to wait for $40-100.
The sooner the better. I’m taking my money to $BCRX after this.
RIH $PLX
Good news coming in the corporate update:
https://ampiopharma.com
When I was in Korea I learned that they use metal chopsticks to detect poison
https://ampiopharma.com/news/ampio-announces-early-positive-data-in-phase-1-trial-of-inhaled-ampion-in-covid-19-respiratory-distress/
See the first paragraph after the bullets.
An RN working at a clinical study site said, “The staff is seeing a big difference in the Ampion-treated patients. We believe Ampion kept one patient off a ventilator – and another discharged this past weekend, no one expected him to live. So now we have both respiratory therapy and nursing stating how they are seeing a big difference in your drug.”
Geert Kersten
@GeertKersten1
·
9m
I cannot sleep. I am so excited. Everything I have dreamt about is coming together. We made it to the finish line of our huge Phase 3 cancer study, just waiting for the final analysis. And, finally, the world is pushing back against the short sellers who almost destroyed $CVM.
If sold for 6.5 billion that’ll be a share price of about $43 per share.
At 7 billion, about $47 a share.
At 7.5 million, about $50 a share.
Does it seem appropriate to upstage all the other companies?
In case you’re interested, her name is Cathie Wood
Geert’s most recent interview:
I’m hoping the Japan approval gets delayed a couple of weeks because I’m waiting for $AUPH to pay off first.
Thanks for the list of catalysts.
Japan might go into lockdown. From the Japan Times:
Koike said that if the situation continues to worsen, the metropolitan government “may have no choice but to request” that Prime Minister Yoshihide Suga declare a state of emergency.
The recent discovery of new strains of the COVID-19 virus ... has warranted “the highest levels of alert and precaution,” the Tokyo governor said.
ongoing analysis would suggest that the trial was not a failure and so analysis continues? If the trial had failed, wouldn’t this bad news be announced immediately or very soon after receiving data?
Looking to enter. Will it go under six dollars? 2021 price target: $20?
They say December 31 is the day.
And then he’s gonna party like it’s
Nine-teen thir-dee-nine.
From the PDF:
Further, a U.S. patent has also been issued covering the voclosporin dosing protocol with a term extending to December 2037, if the FDA incorporates the dosing protocol used in both the AURA and AURORA trials into the product label.
How does their science compare with $AUPH’s science? Aurinia pharmaceutical’s product seems safer and more efficacious. Their dry eyes data will be released in October or November.
How’s the HIV vaccine coming along?
EyeGate’s dry eye success. Up 86% already
https://www.bloomberg.com/press-releases/2020-03-31/eyegate-pharma-announces-positive-topline-data-in-follow-on-dry-eye-pilot-study
Ampio has a treatment for osteoarthritis (not rheumatoid arthritis) which they plan to nebulize for COVID-19. I wonder if the report has oak and rheumatoid arthritis confused.
Doubtful
I’ll keep an eye on it. We should remain civilized
That’s a terms of service violation
From Dr. Sessions (StTwits):
Exposure to the endemic coronaviruses produces immunity that lasts longer than influenza, but not permanent immunity. Coronavirus (CV) immunity is moderately transient. CVs are also fairly poor at maintaining the integrity of their genome, which has the effect that it can mutate frequently. That's why the CV-related common cold is recurrent; mutations and transient immunity.
This is also a reason that CVM LEAPS is a better option than a traditional antibody mediated vaccine. LEAPS targets antigens within COVID-19 that produce T-cell responses. Unlike the mechanism behind antibody based vaccines, these antigens are less variable between viral strains and less likely to change in response to antibodies elicited by prior infection, or other vaccines.
I’m waiting for that price too but I’m gonna hold it $100. What a great pipeline they have
It only seems deadlier. The death rate is higher because there’s no vaccine. Lots of people take vaccines for the flu. That’s why the death rate is lower.
Loading b4 BO. Rinse and repeat
Go. No smug people wanted.
Did you invest $100,000 as usual?
Say what? Who’s asleep at the wheel?
I heard that if it falls 25% within 15 minutes they have to halt it